Company
Headquarters: Thousand Oaks, CA, United States
Employees: 15
CEO: Dr. Paul Pagano Ph.D.
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $219.88 B |
| Danaher | $177.43 B |
| Siemens Healthineers AG | $59.19 B |
| Agilent Technologies, Inc. | $43.57 B |
| Lonza Group Ltd | $41.66 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. It engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. LungLife AI, Inc. was incorporated in 2009 and is based in Thousand Oaks, California.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | £36,662 |
| EBITDA | £-4,286,266 |
| Gross Profit TTM | £46,000 |
| Profit Margin | 100.00% |
| Operating Margin | -11839.13% |
| Quarterly Revenue Growth | 64.30% |
LungLife AI, Inc. has the following listings and related stock indices.
Stock: LSE: LLAI wb_incandescent